UNSPSC 85891109: High dose rate (hdr) brachytherapy of peripheral nerve using palladium 103 (pd-103)

This classification denotes the group of activities that yields a radiation therapy intervention or procedure of high dose rate (hdr) brachytherapy of peripheral nerve using palladium 103 (pd-103). This intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code D0179BZ

UNSPSC 85891109 High dose rate (HDR) brachytherapy of peripheral nerve using palladium 103 (Pd-103) is a Commodity code that shows no recent state and local procurement activity aligned with its nominal scope. The single recent opportunity tagged under this code—County of Santa Clara Health System's request for temporary health professional staffing services—falls outside the code's stated medical procedure domain and represents a mismatch between the code assignment and the work actually being solicited.

The County of Santa Clara Health System posted RFQ RFSQHHSFY270052 on July 7, 2026, with a response deadline of October 7, 2026, seeking to establish a non-exclusive, multiple-award qualified vendor pool for temporary staffing across ancillary clinical categories including audiology, cardiology and vascular, diagnostic imaging/radiology, gastroenterology, health services assistant, medical social worker, ophthalmology, orthopedic, patient transporter, respiratory care, sterile processing, surgical/operating room/labor and delivery, and therapy services. The Health System explicitly excludes nursing, physician, and other non-clinical staffing. Placement on the Qualified List carries no guarantee of contract award or work volume, and qualifications and scope of services are negotiated case-by-case. Given the absence of activity matching HDR brachytherapy procurement and the disconnect between the code's specialized clinical procedure name and the vendor-pool staffing work actually being bought, this code warrants close monitoring for alignment corrections or future oncology-specific opportunities before pursuing vendor qualification.